Export 32 results:
Sort by: Author Title Type [ Year  (Desc)]
Zayed, R. A., H. F. Sheba, M. A. A. K. Elazaem, Z. A. Elsaadany, L. O. Elmessery, J. A. Mahmoud, D. A. R. Rahman, and F. R. Abdou, "B- Cell Activating Factor Promoter Polymorphisms in Egyptian Patients with Systemic Lupus Erythematosus.", Annals of Clinical & Laboratory Science, vol. 43, issue 3, pp. 111-116, 2013. Abstract

Background: Systemic lupus erythematosus (SLE) is a heterogonous autoimmune disease involving
most immune cells. Studies have revealed a number of cytokine pathways that play important roles in
the disease process. Among these are B- cell activating factor (BAFF), which regulates B-cell maturation,
survival, and function. Objective: To study the association between BAFF promoter polymorphism and
systemic lupus erythematosus (SLE). Methods: Single nucleotide polymorphisms in the BAFF promoter
region; -2841 (T>C), -2701 (T>A), -871 (C>T) were investigated by PCR-RFLP genotyping in fifty Egyptian
SLE patients and thirty normal controls. Results: The frequency of mutant alleles of both -871C>T
and -2701 T>A was higher among SLE patients than controls (p-value <0.001 and 0.000 respectively).
There was a highly significant relationship between -871 C>T polymorphism and SLE (P<0.001), with the
sensitivity and the specificity of the test being 100 %, and 70%, respectively. Patients expressing the -2701
T>A allele were seven times more prone to SLE than those with the T/T wild genotype (sensitivity of the
test = 78%, specificity = 66.7%, odds ratio = 7.09, C.I at 95% = 2.29-22.64). Conclusion: Polymorphisms
in the regulatory region of the BAFF gene do contribute to the susceptibility to SLE in Egyptian patients,
which indicates BAFF as a potential therapeutic target.

Gabr, H., R. Zayed, and A. R. Elzayat, "Comparison between Different Cord Blood Stem Cell Populations in Efficiency of Transdifferentiation into Hepatic Lineage.", 1st Annual International Interdisciplinary Conference, AIIC, Azores, Portugal, ESI, pp. 762-768, 2013. Abstract

Background: Cord blood is established as a source of stem cells for hemopoeitic reconstitution. Cord
blood transplants have been performed for more than 20 years now. However, cord blood stem cells
as a source for regenerative medicine is still under trial. The availability of cord blood and its banking
facilities make it a very useful source of hepatocytes for support of endstage liver disease. Cord blood
contains a number of stem cell subsets: CD34+, CD133+, and mesenchymal stem cells (MSCs).
Objectives: This study was conducted to compare between these subsets in hepatocyte
transdifferentiation efficiency. Hepatocyte lineage commitment was evaluated by alpha-fetoprotein
(AFP) expression and albumin synthesis.
Methods: Cord blood is assayed for viability. Magnetic separation was done for CD34+ve, CD133+ve
populations, MSCs were separated by culture on plastic flasks. Each cell fraction (CD34+ve,
CD133+ve and MSCs) was cultured in liquid culture containing hepatocyte growth factor for 7 days.
AFP expression was done using immunocytochemistry, albumin synthesis was measured in culture
supernatant using microalbumin assay kit.
Results: All three populations showed heptocyte transdifferentiation; although with varying
percentages. There was no statistically significant difference in AFP expression with MSCs showing
31% positivity, CD133+ve30% followed by CD34+ve showing 28.8%. Also, MSCs population
showed the highest albumin synthesis levels, followed by CD34+ then CD133+ cells.
Conclusion: Induction of hepatocyte-like cells is possible with all three stem cell subsets of the cord
blood. However, establishment of functional hepatic cells is higher in MSCs population.

EL-BELTAGY, M. O. H. A. M. A. D., A. H. M. A. D. ALY, H. Gabr, R. Zayed, E. H. S. A. N. E. L. GONEIMY, N. E. V. I. N. E. FOUAD, and A. H. M. A. D. ISSA, "Adjuvant Dendritic Cell-Based Tumor Vaccination for Patients with Malignant Glioma", Med. J. Cairo Univ., vol. 78, issue 1, pp. 253-258, 2010.
Zayed, R. A., E. Rushdy, and D. ’aA. Saleh, "Detection of HCV RNA in the Peripheral Blood Mononuclear Cells of Serum HCV RNA Negative Egyptian Patients under Interferon Treatment.", Am J Med Sci., vol. 340, issue 6, pp. 435-438, 2010. Abstract

Despite recent success after the introduction of combination therapy with interferon (IFN)-α and ribavirin, approximately 60% of patients with hepatitis C virus (HCV) genotype 4 fail to respond. Resistance to antiviral therapy remains a serious problem in the management of chronic hepatitis C. In most patients, HCV RNA could be detected in peripheral blood mononuclear cell (PBMC).
The authors aimed to investigate the predictive value of HCV RNA in PBMC of patients with chronic hepatitis C after IFN treatment, which may act as the source of HCV reinfection of hepatic cells.
Seventy patients with chronic hepatitis C were treated with IFN plus ribavirin for 48 weeks; they all achieved clearance of HCV RNA from serum. At the end of treatment, PBMC and serum were examined by real-time polymerase chain reaction for detection of HCV RNA. Six months later, HCV RNA in serum was monitored to detect sustained virologic response.
: Analysis revealed the presence of detectable HCV RNA in the PBMC of 27% of patients despite clearance of serum HCV RNA. During follow-up, 80% of the patients who became serum HCV positive 6 months after the end of treatment had detectable level of HCV RNA in PBMC at the end of treatment.
The absence of HCV in the serum of patients by the end of treatment does not exclude future viremia. The patient might still be a source of infection to others. It is strongly encouraged to test for HCV in PBMC to detect lack of response to treatment and persisting infection.

ElBeshlawy, A., H. G. Metwally, R. A. Zayed, S. M. Mousa, and H. R. F, "The Effect of Freezing on the Recovery and Expansion of Umbilical Cord Blood Hematopoietic Stem Cells", Exp Clin Transplant., vol. 7, issue 1, pp. 50-55, 2009.
Omran, N., Azza M. Ibrahim, H. H. Abou-Elew, and R. A. Zayed, Molecular Detection of Intron 22 Inversion of Factor VIII Gene in Egyptian Hemophilia A Patients, , 2009.
Eyada, T. K., M. A. K. E. Din, M. M. Khorshied, and R. A. Zayed, PRAME and WT1 Genes expression in Chronic Myeloid Leukemia Patients: Clinical Importance and Future Prospects, , 2009.